Our Pipeline

Program

Indication

Discovery

Preclinical

Ph I

Ph II

RESOLVE
IL-1RAP CAR T
CCTx-001
AML
RESOLVE AML-001 (Ph I-II*)
Paediatric AML
MDS
ADVANCE
IL-1RAP ADC
ADV-101
Hematological and solid malignancies
AutoimmuneNot disclosed

Ph I: phase 1; Ph II: phase 2; AML: Acute Myeloid Leukaemia;
MDS: Myelodysplastic Syndrome; CAR T: Chimeric Antigen Receptor T cell;
ADC: Antibody Drug Conjugate; *: pivotal

FPI: First Patient In; Ph I: phase 1; Ph II: phase 2; AML: Acute Myeloid Leukaemia;
MDS: Myelodysplastic Syndrome; CAR T: Chimeric Antigen Receptor T cell;
ADC: Antibody Drug Conjugate; *: pivotal; DC: drug candidate

RESOLVE AML-001 (seamless Ph I-II*)